The New Challenge For The Architect Of Wegovy

 
• By Kevin Grogan

Mads Krogsgaard Thomsen, CEO of the Novo Nordisk Foundation and the man who supervised the development of semaglutide, describes the unprecedented growth of the obesity market and what might come next for Novo.

Mads Thomsen
Mads Krogsgaard Thomsen • Source: Novo Nordisk Foundation

More from C-Suite Speaks

More from Leadership